Biocon Announces Partnership With U.S. Start-Up To Develop Novel Oncologic Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
India’s largest biotech teams with Baltimore’s IATRICa to develop immunoconjugates to fight cancers and infectious diseases.
You may also be interested in...
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Biocon will manufacture biogeneric of Amgen’s Neupogen for Abraxis, the firm tells “The Pink Sheet” DAILY.
Bristol Expands R&D In India Through Biocon Deal
Bristol could open more R&D centers in India as part of the agreement, firm tells “The Pink Sheet” DAILY.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.